What is Cannabis Use Disorder?
Cannabis use disorder (CUD) is a formally recognized psychiatric condition in the DSM-5 characterized by clinically significant impairment or distress from cannabis use, including using more cannabis than intended and difficulty cutting back despite negative consequences. 1
Definition and Diagnostic Framework
CUD represents a dimensional disorder that affects approximately 10% of adults with chronic cannabis use 2. The condition is defined by meeting 2 or more of 11 DSM-5 criteria within a 12-month period, which include:
- Using more cannabis than expected
- Persistent desire or unsuccessful efforts to cut down
- Spending significant time obtaining, using, or recovering from cannabis
- Craving or strong desire to use
- Failure to fulfill major obligations at work, school, or home
- Continued use despite social or interpersonal problems
- Giving up important activities because of cannabis
- Recurrent use in physically hazardous situations
- Continued use despite physical or psychological problems
- Tolerance (needing more to achieve desired effect)
- Withdrawal symptoms upon cessation
The disorder is classified by severity: mild (2-3 criteria), moderate (4-5 criteria), or severe (6+ criteria) 1.
Clinical Significance and Risk Factors
Early onset of cannabis use, especially weekly or daily use, strongly predicts future dependence 2. A randomized trial demonstrated that participants receiving a medical cannabis card had nearly twice the incidence of developing CUD within 12 weeks (17% vs 9%) compared to controls without such cards 2.
Key Risk Factors:
- Age of first use: Younger initiation substantially increases risk 2
- Frequency of use: Daily or near-daily use carries highest risk 2
- High-potency products: THC concentrations have nearly doubled from 9% (2008) to 17% (2017), with concentrates reaching 70% 1
- Psychiatric comorbidity: Cannabis use may increase risk for depressive disorders and exacerbate existing psychiatric conditions 2
Withdrawal Syndrome
Long-term daily cannabis users experience non-life-threatening but clinically significant withdrawal symptoms after cessation 2. These symptoms typically include:
- Irritability and restlessness
- Anxiety
- Sleep disturbances
- Appetite changes
- Abdominal pain
- Headaches 1
Symptoms usually occur within 3 days after cessation and may last up to 14 days 2. The inclusion of cannabis withdrawal in DSM-5 reflects substantial evidence from preclinical, clinical, and epidemiological studies demonstrating its reliability, validity, and clinical significance 3.
Prevalence and Public Health Impact
Among the estimated 193 million cannabis users worldwide, CUD affects approximately 10% 4. In populations with chronic cannabis use, this percentage represents a substantial public health burden, particularly as cannabis legalization increases product availability and potency while decreasing price 4.
The full DSM-5 measure identifies more cases than previous DSM-IV-based proxy measures, particularly through the addition of craving and withdrawal criteria 5. Among those meeting these newer criteria, 25% endorsed craving and 20.3% endorsed withdrawal as key symptoms 5.
Important Clinical Considerations
Comorbidity Patterns
CUD frequently co-occurs with other substance use disorders—89.3% of individuals with CUD use at least one other substance, and 34.2% use two or more substances 6. Mood and personality disorders are particularly prevalent and associated with polysubstance use patterns in CUD cases 6.
Functional Impairment
Severe CUD shows the strongest association with validators across all domains, including psychiatric disorders, social impairment, and functional decline, distinct from mild and moderate CUD which primarily associate with cannabis-specific problems 7. This suggests severe CUD requires more intensive treatment addressing physical, psychiatric, and social functioning 7.
Neurobiological Basis
Individuals with moderate-to-severe CUD demonstrate greater brain activity during cannabis cue exposure in regions involved in salience evaluation, attention, motivation, and disinhibition—consistent with established addiction neurocircuitry 8. This heightened cue reactivity can trigger craving and subsequent use, particularly problematic as cannabis marketing and product visibility increase with legalization 8.
Critical Pitfalls to Avoid
Do not dismiss CUD as less serious than other substance use disorders simply because cannabis is increasingly legalized. The condition carries genuine morbidity through psychiatric complications, functional impairment, and increased motor vehicle accident risk (users are more than twice as likely to be involved in crashes) 2.
Do not overlook the measurement challenge: Studies using legacy diagnostic frameworks may substantially underestimate CUD prevalence despite rising cannabis exposure 9. The transition from DSM-IV to DSM-5 criteria expanded detection of mild and moderate disorder, altering prevalence estimates across populations 9.
Recognize that treatment engagement remains low relative to estimated prevalence, despite evidence supporting psychosocial interventions including cognitive behavioral therapy, motivational enhancement, and contingency management 4, 9. No pharmacotherapies are currently FDA-approved for CUD treatment 4.